Search research articles
Contact Us
Filters
Showing results (161-170 of 205) with videos related to
Page
of 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Kyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
Cancer Discovery
|
March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
Luc Friboulet, Nanxin Li, Ryohei Katayama, et al.
The New England Journal of Medicine
|
December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Alice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.
Science Translational Medicine
|
March 25, 2011
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, et al.
The New England Journal of Medicine
|
June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.
The New England Journal of Medicine
|
June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1
Mark M Awad, Ryohei Katayama, Michele McTigue, et al.
The Lancet. Oncology
|
November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer
Shirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, et al.
Elife
|
November 1, 2017
Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Elsa Beyer Krall, Belinda Wang, Diana M Munoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2012
ROS1 rearrangements define a unique molecular class of lung cancers
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 205) with videos related to
Sort By:
Page
of 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Kyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
Cancer Discovery
|
March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
Luc Friboulet, Nanxin Li, Ryohei Katayama, et al.
The New England Journal of Medicine
|
December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Alice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.
Science Translational Medicine
|
March 25, 2011
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, et al.
The New England Journal of Medicine
|
June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.
The New England Journal of Medicine
|
June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1
Mark M Awad, Ryohei Katayama, Michele McTigue, et al.
The Lancet. Oncology
|
November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer
Shirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, et al.
Elife
|
November 1, 2017
Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Elsa Beyer Krall, Belinda Wang, Diana M Munoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2012
ROS1 rearrangements define a unique molecular class of lung cancers
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, et al.
Page
of 21